Business ❯ Biotechnology ❯ Pharmaceuticals

Drug Development

Clinical Trials Antibody-Drug Conjugates AI in Drug Discovery Obesity Treatments Autoimmune Diseases Contract Manufacturing Research Collaboration Alzheimer's Treatment Vepdegestrant Regulatory Approval Bispecific Antibodies Acquisitions Drug-Fc Conjugates Eli Lilly and Company Multiple Sclerosis Generative AI Regulatory Affairs New Drug Application Genetically Modified Organisms Partnership Strategies Rare Diseases Clinical Research AI in Pharmaceuticals Cystic Fibrosis Cardiovascular Therapeutics CAR-T Therapy Summit Therapeutics siRNA Therapies mRNA Technology Efficacy and Safety Results Protein Therapeutics Oral Therapies

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

The company plans to seek FDA review later this year following the positive late-stage result.

Vertex Heads Into Feb. 12 Earnings With Cautious Market After Mixed Year

Biogen Guides 2026 Profit Above Estimates on Cost Cuts and Leqembi Momentum

Lilly, Repertoire Strike Up-to-$1.93 Billion Autoimmune Drug Pact

Genentech Lifts Holly Springs Biomanufacturing Plan to $2 Billion, Over 500 Jobs

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Sanofi, Dren Bio Set Autoimmune Collaboration Worth Up to $1.7 Billion With $100 Million Upfront

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

aTyr Faces Securities Suit After Phase 3 Failure Triggers 83% Stock Crash

Lilly Steps Up Obesity Push With San Diego Innovation Hub and $6.5 Billion Houston Factory

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

Acadia Halts Carbetocin for Prader-Willi After Phase 3 Miss

ATyr’s Sarcoidosis Drug Fails Phase 3 Goal, Shares Plunge Over 80%